BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 14, 2011
View Archived Issues
Astellas Pharma reviews progress of second quarter fiscal year 2011
Read More
First-in-human data released on candidate hepatitis C therapy
Read More
AstraZeneca reviews progress of third quarter 2011
Read More
Hepatitis C virus resistance characterized in multiple-dose trial of GS-5885
Read More
LB-80380 compared to entecavir in phase IIb trial
Read More
Tocilizumab assessed in large vessel vasculitis
Read More
Ampio Pharmaceuticals reports on Ampion for nasal inflammation
Read More
Scancell to receive second tranche payment for antibody portfolio
Read More
Novel clinical data and analyses presented on Regeneron's rilonacept
Read More
PRT-201 shows promise in patients with kidney disease on hemodialysis
Read More
New PHD2 inhibitors for anemia patented
Read More
Merck & Co. prepares novel fatty-acid amide hydrolase 1 inhibitors
Read More
Novel lysophospholipid S1P1 receptor agonists disclosed by Bristol-Myers Squibb
Read More
Glenmark Pharmaceuticals claims novel phosphodiesterase 10A inhibitors
Read More
Scientists at Janssen synthesize new ketohexokinase inhibitors
Read More
Pharmacokinetics and safety of E-7050 assessed in humans
Read More
High-strength antidepressant gains FDA approval
Read More
FDA removes clinical hold on Helix BioPharma IND application
Read More
Analgesia seen with NP-2 in phase I study
Read More
Ablynx announces proof-of-concept phase II data on ALX-0081
Read More
FDA schedules review of NDA for progesterone vaginal gel
Read More
Alimera receives complete response letter for Iluvien NDA
Read More
EC withdraws marketing authorization for Ablavar
Read More
Phase III study in MS meets primary endpoints
Read More
Kyowa Hakko Kirin and Cephalon begin clinical testing of CEP-37250
Read More